Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN5713-5714-5715 for birch pollen seasonal allergic rhinitis
2020-004094-52Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Nov 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of REGN5713, bremzalerbart and atisnolerbart in allergic rhinitis (AR) and birch pollen allergy (2 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Daily combined symptom and medication score. Started Nov 2020; status: completed.
02
Drugs
REGN5713bremzalerbartatisnolerbart
03
Conditions
allergic rhinitis (AR)birch pollen allergy
Beyond the preview
Go deeper on 2020-004094-52.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004094-52.